Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States

By afschroeder • November 15, 2025

Charles-Schoeman C, Zueger P, McDearmon-Blondell E, Fang S, Peng Y, Oishi T, Jain M, Tesser J. Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States. Rheumatol Ther. 2025 Nov 14. doi: 10.1007/s40744-025-00808-z. Epub ahead of print. PMID: 41239038.

Tags: Biologic disease-modifying antirheumatic drug(bDMARD), Clinical Disease Activity Index(CDAI), Publications, Rheumatoid arthritis(RA), Rheumatology, Tumor necrosis factor inhibitor(TNFi)

Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions

Pahulu I, Calumpit M, Tominez P, Shih JJ, Ebrahimi S, Deville NV, Samoa R, Moin T, Sedrak MS, Valle LF, Steinberg M, Kishan AU, Ganz[...]

The malate-aspartate shuttle supports thermogenic lipid mobilization in brown adipocytes

Veliova M, Ferreira CM, Montales KP, Villalobos F, Brownstein AJ, Acín-Pérez R, Ferreira GS, Jones AE, Stiles L, Divakaruni AS, Liesa M, Shirihai OS, Oliveira[...]

Regional Comparisons of the Prevalence and Socioeconomics of Hepatitis Delta Virus in Two Southern California Counties

Pak K, Leng M, Nguyen J, Moussa K, Gish R, Han SH, Pockros P. Regional Comparisons of the Prevalence and Socioeconomics of Hepatitis Delta Virus[...]